NeuroPace (NASDAQ:NPCE) & Advanced Biomedical Technologies (OTCMKTS:ABMT) Head to Head Survey

NeuroPace (NASDAQ:NPCE) and Advanced Biomedical Technologies (OTCMKTS:ABMT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Insider and Institutional Ownership

78.8% of NeuroPace shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by company insiders. Comparatively, 34.1% of Advanced Biomedical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares NeuroPace and Advanced Biomedical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.47%	-105.67%	-20.01%
Advanced Biomedical Technologies	N/A	N/A	N/A

Volatility & Risk

NeuroPace has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Advanced Biomedical Technologies has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Valuation & Earnings

This table compares NeuroPace and Advanced Biomedical Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99 million	5.73	-$21.47 million	($0.66)	-25.56
Advanced Biomedical Technologies	N/A	N/A	N/A	N/A	N/A

Advanced Biomedical Technologies has lower revenue, but higher earnings than NeuroPace.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for NeuroPace and Advanced Biomedical Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1	1	4	2	2.88
Advanced Biomedical Technologies	0	0	0	0	0.00

NeuroPace currently has a consensus price target of $18.67, suggesting a potential upside of 10.65%. Given NeuroPace’s stronger consensus rating and higher probable upside, equities analysts plainly believe NeuroPace is more favorable than Advanced Biomedical Technologies.

Summary

NeuroPace beats Advanced Biomedical Technologies on 7 of the 11 factors compared between the two stocks.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

About Advanced Biomedical Technologies

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.